These two mid-cap biotech companies are relatively established in their fields — but according to analysts, still have significant upside.
Ultragenyx Pharmaceutical's (RARE) first-quarter 2023 earnings and revenues miss estimates. The company maintains its 2023 guidance.
Ultragenyx (RARE) delivered earnings and revenue surprises of -18.27% and 4.06%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Allogene Therapeutics (ALLO) delivered earnings and revenue surprises of -7.94% and 35%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Zymeworks Inc. (ZYME) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.